Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Trianni Inc. currently faces 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 4 distinct examiners, indicating that every pending matter is assigned to a different individual. These examiners are spread across 3 distinct art units, which suggests some overlap in the departmental oversight of the company's patent applications.
The busiest examiner for this portfolio is SINGH, ANOOP KUMAR, who is responsible for 1 busiest examiner pending action. Since there are 4 pending office actions, the workload is distributed among the 4 distinct examiners. This means the busiest examiner designation is shared among the examiners, though the data highlights this specific individual.
The presence of the 3 distinct art units shows that some examiners are likely working within the same unit. This prosecution environment requires managing relationships with the examiners while also monitoring the trends across the Biotechnology & Pharmaceuticals sector. The distribution of the 1 busiest examiner pending action ensures that no single individual has an outsized influence on the company's entire pending docket.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624084 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | EBBINGHAUS, BRIANA NOEL | 50d overdue |
| 17338408 | ENHANCED PRODUCTION OF IMMUNOGLOBULINS | NICOL, ALEXANDER W | 61d |
| 18557414 | TRANSGENIC RODENTS EXPRESSING CHIMERIC EQUINE-RODENT ANTIBODIES AND METHODS OF USE THEREOF | SINGH, ANOOP KUMAR | 84d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624084 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | EBBINGHAUS, BRIANA NOEL | 50d overdue |
| 18255525 | HEAVY CHAIN-ONLY ANTIBODIES | WILSON, MICHAEL C | 2d overdue |
| 17338408 | ENHANCED PRODUCTION OF IMMUNOGLOBULINS | NICOL, ALEXANDER W | 61d |
| 18557414 | TRANSGENIC RODENTS EXPRESSING CHIMERIC EQUINE-RODENT ANTIBODIES AND METHODS OF USE THEREOF | SINGH, ANOOP KUMAR | 84d |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1638 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557414 | TRANSGENIC RODENTS EXPRESSING CHIMERIC EQUINE-RODENT ANTIBODIES AND METHODS OF USE THEREOF | SINGH, ANOOP KUMAR | 1632 | §102§112 | Non-Final OA | 84d | Pending | Oct 26, 2023 |
| 18255525 | HEAVY CHAIN-ONLY ANTIBODIES | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | 2d overdue | Pending | Jun 01, 2023 |
| 17624084 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112 | Final Rejection | 50d overdue | Pending | Dec 30, 2021 |
| 17338408 | ENHANCED PRODUCTION OF IMMUNOGLOBULINS | NICOL, ALEXANDER W | 1634 | §103§112 | Non-Final OA | 61d | Pending | Jun 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial